Nauman Chaudhry, MD
Assistant Clinical Professor of Ophthalmology and Visual ScienceCards
About
Research
Publications
2024
Aflibercept Biosimilar MYL-1701P vs Reference Aflibercept in Diabetic Macular Edema
Bressler S, Barve A, Ganapathi P, Beckmann K, Apte R, Marcus D, Baumane K, Agarwal S, Oleksy P, Reichstein D, Patel S, Ernest J, Dégi R, Gupta V, Kishino G, Kamei M, Loganathan S, Chaudhry N, Reichstein D, Tabassian A, Fine H, Sjaarda R, Marcus D, Barakat M, Dugel, P, Eichenbaum D, Dessouki A, Berger A, Angle B, Chang M, Patel S, Brown D, Thach A, Baker C, Gordon A, Mansour S, Fox G, Alfaro D, Davies J, Ghorayeb G, Stoller G, Johnson T, Nemcansky J, Rehak J, Studnicka J, Ernest J, Korda V, Veith M, Krzyzanek D, Kalvodova B, Stodulka P, Feltgen N, PD K, Grisanti S, Gamulescu M, Kellner U, Sekundo W, Dahlke C, Zeitz O, Baumane K, Laganovska G, Ozolina S, Vajas A, Seres A, Tsorbatzoglou A, Radnoti J, Kiss K, Gombos K, Degi R, Varsanyi B, Kerenyi A, Noge S, Muramatsu T, Kaga T, Oh H, Watanabe M, Oshima Y, Fujita H, Kishino G, Hanemoto T, Murata K, Kitaoka T, Saito I, Tanabe T, Ebihara N, Imaizumi H, Ishii K, Kamei M, Furuta M, Ojima A, Sawada O, Kawasaki T, Otake H, Doi N, Abe, K, Matsuda S, Kobayashi N, Yoshizumi Y, Budzinskaya M, Lebedev O, Eremina A, Zolotarev A, Izmaylov A, Samoylov A, Astakhov S, Astakhov Y, Shkvorchenko D, Narayanan R, Agarwal K, Rahul S, Natesh S, Gupta V, Panchal B, Kaza H, K M, Agrawal V, Elhence A, Behera U, Raj L, Mazumdar S, Kannan N, Yadav N, Vohra R, Aggarwal S, Sonawane A, Saravanan V, Chauhan R, Fluder E, Nawrocki J, Wylegala E, Zalewski D, Oleksy P, Borcz E. Aflibercept Biosimilar MYL-1701P vs Reference Aflibercept in Diabetic Macular Edema. JAMA Ophthalmology 2024, 142: 952-960. PMID: 39264599, PMCID: PMC11393752, DOI: 10.1001/jamaophthalmol.2024.3458.Peer-Reviewed Original ResearchBest-corrected visual acuityDiabetic macular edemaCentral subfield thicknessEarly Treatment Diabetic Retinopathy StudyAflibercept groupAntidrug antibodiesAdverse eventsWeek 8Aflibercept armMacular edemaIncidence of treatment-emergent adverse eventsPrimary outcomeBaseline BCVA letter scoreTreatment Diabetic Retinopathy StudyTreatment-emergent adverse eventsIncidence of adverse eventsConsecutive intravitreal injectionsDiabetic Retinopathy StudyRandomized clinical trialsType 2 diabetesStudy eyesSubfield thicknessDouble-maskedIntravitreal injectionRetinopathy StudyEndophthalmitis in Eyes Treated with the Port Delivery System with Ranibizumab Summary of Cases during Clinical Trial Development
Eichenbaum D, Freeman W, Chang M, Brooks L, Chaudhry N, Dadgostar H, McCannel C, Michels M, Mittra R, Wolfe J, Beindl V, Jaycock P, Bobbala A, Gune S, Spicer G, Callaway N. Endophthalmitis in Eyes Treated with the Port Delivery System with Ranibizumab Summary of Cases during Clinical Trial Development. Ophthalmology Retina 2024, 9: 127-143. PMID: 39154860, DOI: 10.1016/j.oret.2024.08.005.Peer-Reviewed Original ResearchPort Delivery SystemEndophthalmitis casesConjunctival complicationsFollow-upNeovascular age-related macular degenerationBox warningTreated with intravitreal antibioticsAge-related macular degenerationMonthly intravitreal ranibizumabRisk of endophthalmitisPDS implantUS prescribing informationImmediate postoperative periodClinical trial developmentETDRS lettersIntravitreal antibioticsIntravitreal ranibizumabDelivery systemSafety populationVisual outcomeMacular degenerationOcular proceduresRetrospective reviewVision lossEndophthalmitis
Get In Touch
Contacts
Academic Office Number